Torres, Paola
Cañete, Fiorella
Núñez, Laura
Aguilar, Ariadna
Mesonero, Francisco
Calafat, Margalida
Fernández, Cristina
Teniente, Aïna
Mañosa, Míriam
López-Sanromán, Antonio
Domènech, Eugeni http://orcid.org/0000-0002-2315-7196
Article History
Received: 27 October 2019
Accepted: 10 December 2019
First Online: 19 December 2019
Compliance with Ethical Standards
:
: Laura Núñez has received educational grants from Janssen; Míriam Mañosa has served as a speaker and has received research or educational funding from MSD, AbbVie, Takeda, Janssen, Ferring, and Pfizer; Francisco Mesonero has served as a speaker for Janssen, MSD, Takeda y Abbvie; Fiorella Cañete has served as a speaker or has received educational grants from Takeda, Janssen, MSD, and Ferring; Margalida Calafat has served as a speaker for Takeda, Janssen, Faes Farma and MSD; Antonio López-Sanromán has served as a speaker, a consultant and an advisory member for or has received research funding from MSD, Abbvie, Pfizer, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Gebro Pharma, and Vifor Pharma; Eugeni Domènech has served as a speaker or has received research or educational funding or advisory fees from MSD, AbbVie, Takeda, Kern Pharma, Pfizer, Janssen, Celgene, Adacyte Therapeutics, Otsuka Pharmaceuticals, Ferring, Shire Pharmaceuticals, Tillots Pharma, Thermofisher, Grifols, and Gebro. The remaining authors declared no conflicts of interest.
: This is a retrospective study based on the local databases of the ENEIDA registry (a nationwide registry of IBD patients promoted by the Spanish Working Group in Crohn’s disease and Ulcerative Colitis-GETECCU). The registry was approved by the Ethics Committees at both centers, and all patients gave their informed consent.